Ivermectin
DrugIvermectin at 600mcg/kg in addition to albendazole will be provided for 1 or 3 days.
NCT Number: NCT04041453
There are four species of intestinal worms collectively known as soil-transmitted helminthiasis (STH): Ancylostoma duodenale and Necator americanus (hookworms), Ascaris lumbricoides (roundworms), and Trichuris trichiura (whipworms). These parasites affect over two billion people and contribute to significant morbidity and disability, especially in high risk groups, for example children, agricultural workers and pregnant women. In children, STH are associated with impaired nutritional status evidenced by stunting, thinness and underweight.
As is the case in most Latin America, STH are a public health problem in Honduras. The World Health Organization (WHO) informs that more than 2.5 million children (under 15 years of age) in the country are at risk of infection. To control these infections Honduras has established a national deworming program that operates since 2001 but despite these efforts, the prevalence of STH infections remains unacceptably high. This is especially true in rural communities where prevalence can be as high as 70% of the children population.
Ivermectin (IVM) in combination with albendazole (ALB) has demonstrated the capacity to improve efficacy compared to any of these drugs in monotherapy; the efficacy is however, still inadequate in terms of cure rate, although egg reduction rates are significant.
The purpose of the current trial is to assess the safety and efficacy of 3 experimental regimens for the treatment of infections by Trichuris trichiura in children in comparison with the current standard of practice in Mass Drug Administration (MDA) campaigns. The experimental regimens will explore the effect of multiple day regimens and high dose ivermectin.
Treatment arms:
* Group 1: single dose of ALB 400 mg. (active control arm). N:39 * Group 2: single dose ALB 400mg + IVM 600µg/Kg. N: 57 * Group 3: daily dose ALB 400mg for 3 consecutive days. N:24 * Group 4: daily dose ALB 400mg + IVM 600µg for 3 consecutive days. N:57
Total Study Population: 177
Looking for future studies?
Notify Me2 year–14 year
All sexes
Interventional
Phase 2
IIET, Orán, Salta Province, Argentina
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ivermectin at 600mcg/kg in addition to albendazole will be provided for 1 or 3 days.
Albendazole will be provided as an active control or in experimental arms for 1 or 3 days with ivermectin.
Time frame: 21 days
Number of individuals cured from Trichuris trichiura infection using the duplicate Kato Katz laboratory method on a single sample of fresh stools as the measurement tool. Cure rate is defined as the absence of Trichuris trichiura eggs in post-treatment samples.
Time frame: 21 days
Calculation details: 100 x (1 - arithmetic mean fecal egg count post-intervention / arithmetic mean fecal egg count pre-intervention) Egg change rate was calculated across all participants, as described in reference: Levecke B et al., PLoS Negl Trop Dis. 2014;8(10).
Time frame: 21days
Measurement of the incidence of mutations of tubulin in Trichuris trichiura eggs collected pre and post treatment using molecular biology techniques.
This data is not available yet due to the COVID-19 pandemic, but the data will be available and reported in the future. Anticipated reporting date for this outcome measure is estimated by 2021 and will be confirmed once the pandemic is over.
Alejandro Krolewiecki
Other
Prospective, Parallel-group, Open-label Randomized Controlled Trial of Four Treatment Regimes for Trichuriasis in Pediatric Patients
Acronym: HI4T
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05914363
Adenophorea Infections, Ascaris Lumbricoides Infection
Kwale, Kwale County, Kenya
View Trial DetailsNCT07258173
Adenophorea Infections, Enoplida Infections
View Trial DetailsNCT03435718
Adenophorea Infections, Enoplida Infections
View Trial DetailsNCT03014167
Filariasis, Helminthiasis
Comé, Benin
View Trial Details